The Jim Turner Chair in Cognitive Disorders at the Vanderbilt University School of Medicine shared how the previous muscarinic agonists have better informed the development of this investigational agent, VU319.
Videos
The director of Parkinson’s Disease and Movement Disorders Program at Henry Ford Hospital discussed this pipeline of therapies and the enhancement of the clinical understanding of the disease.
The director of the MedStar Georgetown University Hospital Headache Center stressed building a culture of teaching patients to be their own advocates and to build the relationship with the patient to better manage their migraines.
The director of the MedStar Georgetown University Hospital Headache Center discussed the development of acute care options for patients to improve their quality of life and the management of their condition.
The director of the Hartford Headache Center spoke about the trend toward device use in migraine treatment, and some of the reasons that may have prompted it.
An FDA Warning Letter, the Amyloid Hypothesis and Alzheimer Disease, Adverse Events with Triptan Use
Neurology News Network for the week of November 17, 2018.
The director of the Hartford Healthcare Headache Center in Connecticut and lead investigator on the trial provided some insight into the study's findings.
The associate professor at NYU Langone discussed several of the questions that remained unanswered about the relationship between sleep and Alzheimer disease.
Albertson discussed this facet of stroke care, and all the things being done outside just the clinic to help improve outcomes.
The associate professor at NYU Langone discussed emerging evidence that suggests that sleep disruption results in higher levels of markers associated with Alzheimer disease.
The medical director of the UCSF Multiple Sclerosis Center discussed the idea behind remyelination and shared his thoughts on what the best shot at developing a therapy might be.
The Anne Parrish Titzell Professor of Neurology and Neuroscience at Weill Cornell Medicine’s Feil Family Brain and Mind Research Institute spoke about the cost the condition has for patients and their families.
Neurology News Network for the week of November 10, 2018.
Recent work demonstrates that the anterior part of the hypothalamus is enlarged in cluster headache.
The professor of neurology at Virginia Commonwealth University discussed all the progress that’s been made in the space and shared her thoughts on the advances.
The Global Medical Lead for Migraine and Headache at Teva Pharmaceuticals provided insight into how fremanezumab has helped to improve these facets of the condition.
The neurologist discussed an analysis of findings suggesting that opiate agonists may have a role in the treatment of narcolepsy.
Neurology News Network for the week of November 3, 2018.
The neurologist from Cleveland Clinic discussed the challenges of treating progressive MS, and shared his clinical experience with ibudilast.
The epileptologist discussed this challenge, and shared her thoughts on how to maintain this communication.
The associate professor of neurology and neuroscience at Weill Cornell Medicine discussed this work, and what she and her colleagues believe could be addressed by a successful effort.
The study presents direct evidence that subjective experiences of insomnia may be coupled to the REM sleep state.
Striking findings are a call for public policy and research initiatives for aging populations with neurologic conditions.
The study found that there has been a significant increasing trend in patients with migraine—irrespective of aura status—having an ischemic stroke.
Heidbreder further described the current understanding of the condition and what she and her colleagues have found out.
For the director of the Johns Hopkins Multiple Sclerosis Center, a biomarker is perhaps only as useful as the clinician community’s ability to read out its measurements.
Neurology News Network for the week of Oct. 27, 2018.
The Psychiatrist at Psychiatric Services Solothurn and University of Basel discussed how heart rate variability correlates with sleep stages, which may indicate nocturnal brain activity.
Despite some mistrusting the abilities of imaging to aid in therapeutic development, a new MRI method could better inform the anatomical understanding of the striatum.
Under treatment, the dynamic of REM sleep related heart rate variability shows early changes during the first week, providing a promising biomarker of treatment.
Advertisement
Advertisement
